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Abstract 
 
Objective: To examine the potential impact of visual personalised biomarker feedback on 
intention to stop smoking and to evaluate possible underlying causal pathways. 
 
Design: This study is a pilot for a randomised controlled trial. Outcome measures were 
assessed immediately after the intervention and at four weeks follow-up. 
 
Method: Twenty-three smokers attending a cardiovascular outpatient clinic in London 
were randomly allocated to one of two groups: to either receive a print-out of an 
ultrasound image of their carotid artery showing atherosclerotic plaque alongside an 
image of a disease-free artery, or to receive routine verbal feedback. 
 
Results: The intervention significantly increased perceptions of susceptibility to smoking-
related diseases (χ2=5.24, p<.05) and led to an increase in intentions to stop smoking. 
The latter was moderated by self-efficacy: the intervention increased intention to stop 
smoking only in people with higher levels of self-efficacy in stopping smoking 
(t(10)=2.33, p<.05). 
 
Conclusions: This study provides preliminary support for the potential effectiveness of 
personalised biomarker feedback to increase intentions to stop smoking. It also 
highlights the need to target and increase self-efficacy in smoking cessation 
interventions. 
 
 
 
Key words: harm biomarker feedback, smoking cessation intervention, atherosclerotic 
plaque, cardiovascular patients, extended parallel processing model, self-efficacy 
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1. Introduction 
 
Smoking remains one of the most enduring public health problems of modern society, 
killing over 4.9 million people per year worldwide (World Health Organization (WHO), 
2002). Stopping smoking can prevent the development of tobacco-related diseases 
within a few years of cessation (Peto et al., 2000; Rich-Edwards, Manson, Hennekens, & 
Buring, 1995). The fact that 70-80% of smokers would like to quit, but only half of 
smokers ever achieve abstinence (World Health Organization (WHO), 1998), underlines 
the need for the development of more effective interventions, which both motivate 
smokers to quit and help sustain long-term cessation. 
 
One promising approach for smoking cessation interventions is the use of personalised 
information of smoking-induced health damage provided by biomarker feedback 
(Lerman, Orleans, & Engstrom, 1993). Its inclusion in cessation programmes has been 
proposed on the basis of theoretical considerations: to simply tell people they are at risk 
of developing a disease is rarely sufficient to change behaviour (Leventhal et al., 1997). 
Personalised information can counteract perceptions of invulnerability to the health 
consequences of tobacco-use, which are common among smokers (Strecher, Kreuter, & 
Kobrin, 1995), thus raising threat perceptions and fear, which motivate behaviour 
change to reduce this threat (Cameron, 2003). 
 
According to the Extended Parallel Process Model (EPPM, Witte, 1998) people engage 
in protective behaviours when they perceive themselves to be at risk of a threat (threat 
appraisal) and feel that they can reduce this threat (efficacy appraisal). People first 
appraise the threat by evaluating the severity of the threat (e.g. trivial or serious) and 
their susceptibility to it. This is followed by an efficacy appraisal. This involves an 
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assessment of their ability to perform a behaviour (self-efficacy) that is effective in 
averting this threat (response efficacy). 
 
When both threat and efficacy appraisals are high, danger control processes ensue, 
which lead to the acceptance of a threat message such as “stop smoking”. In this 
context, fear (resulting from high threat appraisal) may guide people towards a 
behavioural solution, i.e. cessation. However, when threat appraisal is high and efficacy 
appraisal is low, fear could lead people towards a cognitive solution (i.e. avoidance) and 
fear control processes take over, which can result in the rejection of the threat message 
(Witte & Allen, 2000).  
 
Biomarker feedback may increase smokers’ threat perceptions, and thus instigate 
smoking cessation, for a variety of reasons. Visual personalised biomarker feedback 
showing harm is postulated to maximally impact on threat perceptions as imagery allows 
for the spanning of the conscious-unconscious continuum more readily than language 
(Horowitz, 1970) and is therefore less likely to be filtered through the conscious critical 
apparatus. Consequently, visual personalised biomarker feedback would increase the 
likelihood of danger control processes occurring since it avoids derogation of the threat 
message by “disengagement beliefs”, which distort the threatening meaning of 
potentially motivating information (Bandura, Barbaranelli, Caprara, & Pastorelli, 1996). 
Imagery with reference to the self also leads to greater problem elaboration and more 
stable changes in attitude (Burnkrant & Unnava, 1995). 
 
However, as visual personalised biomarker feedback showing harm does not increase 
perceptions of self-efficacy, its impact on cognitive and behavioural responses may be 
particularly pronounced in smokers with higher levels of self-efficacy. For instance, in the 
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absence of sufficient self-efficacy, a threat message does not increase motivation to stop 
smoking (Bishop, Marteau, Hall, Kitchener, & Hajek, 2005). In contrast, perceptions of 
response efficacy may be increased either by the provision of information (e.g. outlining 
a behaviour-disease link) or by a biomarker evidencing the positive impact of a 
behaviour (e.g. smoking cessation) on an objective outcome (e.g. lung function 
improvement). 
 
An earlier unreplicated study, which was not theoretically based, demonstrated that 
providing healthy smokers with ultrasound photographs of their own atherosclerotic 
plaque increased quit rates (Bovet, Perret, Cornuz, Quilindo, & Paccaud, 2002). The 
current study was set in a cardiovascular disease (CVD) outpatient clinic. Non-
hospitalized smokers would particularly benefit from smoking cessation since the 
development of smoking-induced diseases like atherosclerosis1 can be halted, if not 
reversed, after smoking cessation (Wiggers, Smets, de Haes, Peters, & Legemate, 
2003). The objective of this study was to assess the motivational impact of personalised 
biomarker feedback and to explore possible causal pathways as postulated by the 
EPPM, as well as the acceptability and feasibility of such an approach in a clinical 
setting. Our hypotheses were as follows: 
 
a.) Showing CVD outpatients who smoke images of their damaged arteries increases 
threat perceptions, i.e. perceptions of susceptibility and severity. 
b.) Showing CVD outpatients who smoke images of their damaged arteries and 
providing them with information about the link between smoking and CVD increases 
response efficacy but not self-efficacy perceptions. 
                                                 
1
 In atherosclerosis smooth muscle cells proliferate and fatty substances, in particular cholesterol and 
triglycerides, accumulate in the walls of arteries to create plaque (Tortora & Grabowski, 2002) 
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c.) Showing CVD outpatients who smoke images of their damaged arteries increases 
intention to stop smoking, particularly in smokers with higher levels of self-efficacy. 
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2. Methods 
Participants 
This study was approved by Guy's Hospital Research Ethics Committee (Ref 
2004/02/02). Between April and July 2004 cardiovascular outpatients at a London 
hospital were sent written information about this study one week prior to their clinic 
appointments. On the day of their appointments, patients who were smokers and literate 
in English were invited to participate in the study. Demographic and baseline 
characteristics of the sample are shown in Table 1. These indicate that the majority of 
patients were likely to be older and had no formal education. They also displayed high 
nicotine dependence as more than half of patients reported smoking within thirty minutes 
of waking and consuming more than eleven cigarettes per day. 
 
Procedure 
By means of a computer generated random numbers table consenting patients were 
allocated to either the intervention or the control group (routine care) and asked to fill in 
a baseline questionnaire. Both groups were then seen by a trained clinician who imaged 
their carotid arteries. This is a routine clinical procedure, which lasts about five minutes 
and uses a high-frequency ultrasound transducer (Philips HDI 5000, Letchworth, UK). 
Following the scan, patients in both groups were seen by a cardiovascular consultant 
who provided them with verbal feedback of the scan result. In addition to this routine 
care, the consultant showed people in the intervention group their scans and gave them 
photographs contrasting a healthy artery with their own arteries, together with a leaflet 
describing the link between CVD and smoking as well as general health benefits of 
smoking cessation. After their appointments, all participants were given a follow-up 
questionnaire to complete. Patients in the intervention group were also briefly 
interviewed about their feelings regarding the scan, and asked to provide any thoughts 
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about or problems with this procedure. Four weeks after the clinic date, patients were 
telephoned to obtain follow-up information. 
 
Measures  
The baseline questionnaire assessed demographic details (age, gender, educational 
attainment), nicotine dependence (Fagerstrom, 1978) and readiness to stop smoking 
(Prochaska & DiClemente, 1983). The first follow-up questionnaire assessed intention to 
stop smoking in the next month, perceived susceptibility to and perceived severity of 
smoking-related illnesses, perceived response efficacy of stopping smoking and 
perceived self-efficacy to do so. These were each measured with two 7-point scales, e.g. 
‘Do you intend to stop smoking in the next month?’ from ‘definitely do not’ to ‘definitely 
do’ and ‘How likely is it that you will stop smoking in the next month?’ from ‘very unlikely’ 
to ‘very likely’. The combined scales were reliable (Cronbach's alphas 0.71-0.87) and 
their means were used in the analysis (for more details of measures see Hall, Weinman, 
& Marteau, 2004). 
 
At the four week telephone follow-up, various smoking cessation behaviours (use of 
cessation services and products, quit attempts, talking to a GP or a nurse at a primary 
care centre about quitting, calling a stop-smoking helpline) were assessed. Engagement 
in these behaviours predicts the transition from smoking to non-smoking (France, 
Glasgow, & Marcus, 2001).  
 
Analyses 
Parametric assumptions were tested and group comparisons were conducted using 
either t-tests or, if results indicated a non-parametric distribution, χ2 and Mann-Whitney 
U tests. Interaction effects were explored with univariate ANOVA. As the current study 
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was powered only to detect large effects, Cohen’s d and h (Cohen, 1988) were also 
calculated to estimate effect sizes. Qualitative data on open-ended questions were 
analysed using content analysis (Boyatzis, 1998). As is recommended procedure (Willig, 
2001), reliability and validity of reported findings were assessed by an independent audit 
involving an outside researcher. 
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3. Results 
The two groups did not differ on any demographic variables or baseline readiness to 
stop smoking (Table 1). All but two patients in the treatment group had abnormal arteries 
and there were no differences in scan results between the two groups. 
 
Table 1 about here 
 
a.) Perceptions of the severity of CVD were similarly high in both groups (Table 2). Since 
susceptibility scores showed a markedly different shape of distribution between groups, 
this measure was dichotomised. Compared to the control group, the intervention group 
reported higher perceptions of susceptibility to smoking-related diseases (Cohen's h= 
0.99). 
 
Table 2 about here 
 
b.) Perceptions of response efficacy did not differ significantly between groups. As 
hypothesised, there were no significant differences between groups in perceived self-
efficacy. 
 
c.) Immediately after the scan, the two groups did not differ significantly in reported 
intention to stop smoking. However, the mean difference was in the expected direction 
evidencing a medium-sized effect. At follow-up, those in the intervention group were also 
more likely to report engaging in smoking cessation behaviours (Cohen's h=0.79, Table 
2).  
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As this study was powered to detect only large effect sizes, and because of the 
observed ceiling effect in some threat and efficacy measures, interactions between 
these measures and group allocation on intention to stop smoking could not be 
investigated. The analysis was therefore limited to self-efficacy. As postulated, self-
efficacy interacted with group on intention to stop smoking (F(1,19)=5.73, p=.03; Figure 
1). Compared to the control group, the intervention increased intentions to stop smoking 
only in patients with high levels of self-efficacy (t(10)=2.33, p<.05) and not in those with 
low levels of self-efficacy (t(9)=-1.031, n.s.). 
 
Figure 1 about here 
 
In order to assess the acceptability of the intervention, patients in the intervention group 
were briefly interviewed after their scan to ascertain their views about the procedure. 
They unanimously reported that the scan was unproblematic and did not make them feel 
uncomfortable or scared. At follow-up, only patients in the intervention group mentioned 
that their clinic visit had made them think more seriously about giving up smoking. 
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4. Discussion 
 
Despite the relatively small sample size and short follow-up, the results of this pilot study 
are encouraging. As hypothesised, patients who received personalised biomarker 
feedback visualising harm reported higher susceptibility to heart disease, indicating that 
this feedback increased their awareness of this smoking-related risk. Confirming 
previous research involving biomarker feedback (McClure, 2001), there was some 
evidence that the intervention altered both motivational and behavioural outcomes. 
Patients in the intervention group had a higher mean intention to stop smoking and 
reported engaging in more cessation behaviours including attempting to quit and 
contacting quit-smoking services. Although these group differences were not statistically 
significant, the effect sizes are suggestive of the potential effectiveness of the 
intervention. 
 
Contrary to expectation, the study groups did not differ in their perceptions of response 
efficacy despite the provision of information about the effectiveness of smoking 
cessation in the intervention group. This probably reflects characteristics of the study 
population. Patients suffering from CVD have direct experience of the consequences of 
the disease and, through previous consultations, are also likely to have been exposed to 
relevant information regarding the benefits of cessation resulting in both high levels of 
perceived severity and response efficacy. 
 
In contrast to response efficacy, the intervention did not attempt to alter self-efficacy 
perceptions and group differences on this measure were therefore not anticipated. 
However, among smokers with higher self-efficacy to stop smoking the intervention had 
a significant impact on intention to quit. This moderation is consistent with previous 
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research (Bishop et al., 2005) and in agreement with the predictions of EPPM. Showing 
patients with CVD images of their own arteries increased threat perceptions but only 
smokers with high self-efficacy subsequently engaged in danger control processes and 
accepted the health warning as shown by an increase in intention to stop smoking. In 
contrast, patients with lower self-efficacy engaged in fear control in response to the 
intervention and rejected the message thus displaying somewhat lower intentions to stop 
smoking. In terms of research practice, this finding highlights the need for smoking 
interventions to include procedures that increase smokers’ self-efficacy levels in order to 
obtain optimal results. 
 
This intervention was easy to implement without interrupting the clinic timetable. As most 
cardiovascular disease clinics use ultrasound transducers, the intervention is likely to be 
cost- and time-effective, requiring approximately five minutes of clinicians’ time. 
Interviews with patients showed the intervention to be acceptable to them, and at follow-
up, some commented that they felt it had helped them become more determined to deal 
with their smoking habit.  
 
This pilot study provides preliminary evidence of the feasibility, acceptability and 
potential effectiveness of a novel smoking intervention to increase intentions to stop 
smoking. Providing patients with an image of their own arteries could create an 
opportune moment during which smokers are more amenable to quit-advice or referrals 
to specialist smoking clinics. This minimal intervention could supply the crucial initial 
motivation to stop smoking for patients who are already suffering from a smoking-related 
condition. However, this effect may be restricted to smokers with a higher level of self-
efficacy and a clinical trial is now needed to assess its effectiveness on sustained 
smoking cessation.
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 Table 1 Demographic and baseline characteristics 
Categorical Variables 
Total 
Sample 
(N=23)  
Intervention 
Group 
(N=11) 
 
Control 
Group 
(N=12) 
Test of 
Differences  
Proportions (N) 
Sex 
Female 47.8 (11)  36.4   (4)  58.3   (7) χ2=1.11, 
n.s. Male 52.2 (12)  63.6   (7)  41.7   (5) 
Education 
No Qualification 73.9 (17)  81.8   (9)  66.7   (8) 
U = 53.0, 
n.s. 
GCSE   4.3   (1)    9.1   (1)        - 
A Level 13.0   (3)    9.1   (1)  16.7   (2) 
Higher Education   8.7   (2)        -  16.7   (2) 
Daily cigarette 
consumption 
(in cigarettes) 
10 or less 39.1   (9)  36.4   (4)  41.7   (5) 
U = 62.5, 
n.s. 
11-20 52.2 (12)  54.5   (6)  50.0   (6) 
21 or more   8.7   (2)    9.1   (1)    8.3   (1) 
Daily smoking 
start (in min-
utes after 
waking) 
After 60 13.0   (3)  18.2   (2)    8.3   (1) 
U = 59.5, 
n.s 
Within 31-60 34.8   (8)  45.5   (5)  25.0   (3) 
Within 6-30 30.4   (7)        -  58.3   (7) 
Within 5 21.7   (5)  36.4   (4)    8.3   (1) 
Readiness to 
stop smoking 
in: 
Next month 13.0   (3)  18.2   (2)    8.3   (1) 
U = 56.5, 
n.s. 
Next 6 months 65.2 (15)  63.6   (7)  66.7   (8) 
Next 5 years   8.7   (2)    9.1   (1)    8.3   (1) 
Not next 5 years 13.0   (3)    9.1   (1)  16.7   (2) 
Continuous Variable Mean (SD)  
Age (in years) 62.8 (11.6) 
 
61.91 (9.2)  63.67 (13.8) 
t(21)=-0.36, 
n.s. 
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Table 2 Outcome variables by group 
With the exception of smoking cessation behaviours at 4 weeks, all outcomes were assessed 
immediately after the intervention 
Continuous Variables 
Intervention 
Group (N=11) 
 
 
Control Group 
(N=12) 
Effect size  
(Cohen’s d) Mean (SD) 
Intention to stop smoking in the 
next month 
4.0 (1.8)  3.3 (1.5) 0.44, t(21)=1.04, ns 
Perceived self-efficacy 3.1 (1.6)  3.0 (2.0) 0.06, t(21)=0.18, ns 
Perceived response efficacy 5.1 (1.3)  5.0 (1.9) 0.06, t(21)=0.26, ns 
Perceived severity 5.8 (1.8)  6.0 (0.9) 0.15, t(21)=-0.39, ns 
 Categorical Variables Proportions (N) (Cohen's h) 
Perceived  
Susceptibility 
Low 27.3  (3) 
 
      75    (9) 
0.99, χ2=5.24, p=.02 
High 72.7  (8)        25    (3) 
Smoking Cessation 
Behaviours at 4 
week follow-up 
None 9.1    (1)        41.7 (5) 
0.79, χ2=3.16, p=.08 
At least one 90.9 (10)        58.3 (7) 
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Figure Legend 
 
Figure 1: Impact of intervention on intention to stop smoking for smokers with higher and 
lower levels of self-efficacy; ^Median split scale (lower self-efficacy: 1-2.5, higher self-
efficacy: 3-7); *p<.05 
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